skip to the content

Clinical Trials

Colorectal Cancer Study

S0600, Phase III Trial of Irinotecan-based chemotherapy plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for patients with Metastatic Colorectal Cancer who have Progress on Bevacizumab with either FOLFOX, OPTIMOX or XELOX

Protocol ID

07.06.123

Protocol Description

The purpose of this study is to compare the effects, good and/or bad, of not adding bevacizumab or of adding either a lower dose or a higher dose of bevacizumab to cetuximab plus an irinotecan-based treatment for colorectal cancer. The standard treatment is chemotherapy with a combination of drugs that includes irinotecan and cetuximab.  The research part of this study is the continuation of bevacizumab in lower doses, higher doses or not at all. We want to know the effects of these doses on patients and their colorectal cancer to find out which is better.

Eligibility Criteria

Patients with colorectal cancer

Primary Investigator(s)

  • Bhoomi Mehrotra, MD

Contact Information

Dale Janson, RPA-C
(718) 470-4408
djanson@lij.edu

Last Update

March 26, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top